|
Post by daduke38 on Apr 8, 2016 17:08:06 GMT -5
Source says Matt is still negotiating a Sanofi settlement as of today and that the next Afrezza partners will be multiple small regional partners in the size of RLS $100M deal each. It won't be a single BP like SNY, in case you wonder where the funding sources come from for many critical hires. LOL. What sources? The sources that told you all the other things that never came true? Pump pump pump away. Pump the price for me as well. Holding heavy bags Don't be so sure that Lakers is pumping! Some will understand this comment more than others!!!!!!!
|
|
|
Post by navpoon on Apr 8, 2016 18:38:45 GMT -5
Lakers has been on except for SNY ending partnership. Everyone was blind sided by that....even management though they I think they did see the writing on the wall.
|
|
|
Post by sportsrancho on Apr 8, 2016 19:02:23 GMT -5
Lakers has been on except for SNY ending partnership. Everyone was blind sided by that....even management though they I think they did see the writing on the wall. You're right. I think they saw the writing on the wall. But didn't see it coming when it did. Lakers IMO nailed it today!
|
|
|
Post by bradleysbest on Apr 8, 2016 19:12:00 GMT -5
If true, should we not have a partnership or 2 already done since it will be regional small partnerships? Just wish we had some info or direction this week from Matt. Thoughts? #freedom
|
|
|
Post by nylefty on Apr 8, 2016 19:25:01 GMT -5
Matt has said that under the agreement with Sanofi he couldn't even negotiate with other companies until Afrezza was returned. It's only been four days...hardly enough time to cross all the t's and dot all the i's.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 8, 2016 19:27:59 GMT -5
Source says Matt is still negotiating a Sanofi settlement as of today and that the next Afrezza partners will be multiple small regional partners in the size of RLS $100M deal each. It won't be a single BP like SNY, in case you wonder where the funding sources come from for many critical hires. LOL. What sources? The sources that told you all the other things that never came true? Pump pump pump away. Pump the price for me as well. Holding heavy bagstar Pipe down you This is therapeutic for me. I don't necessarily believe it but I'm regaining momentum off of my long thesis, so it's nice to hear. Lakers is a respectable poster, and has been for years. "It won't be a single BP like SNY, In case you wonder where the funding sources come from for many critical hires."
|
|
|
Post by kc on Apr 8, 2016 20:11:05 GMT -5
Source says Matt is still negotiating a Sanofi settlement as of today and that the next Afrezza partners will be multiple small regional partners in the size of RLS $100M deal each. It won't be a single BP like SNY, in case you wonder where the funding sources come from for many critical hires. LOL. What sources? The sources that told you all the other things that never came true? Pump pump pump away. Pump the price for me as well. Holding heavy bags Newbie, don't come along and try to stir the pot, most of us on this board respect Lakers view. Have some respect before you start making sarcastic comments.
|
|
|
Post by sccrbrg on Apr 8, 2016 20:14:46 GMT -5
LOL. What sources? The sources that told you all the other things that never came true? Pump pump pump away. Pump the price for me as well. Holding heavy bags Newbie, don't come along and try to stir the pot, most of us on this board respect Lakers view. Have some respect before you start making sarcastic comments. In his defense, Lakers made a LOT of prognostications on YMB that were way off base, and several on here.
|
|
|
Post by jerrys on Apr 8, 2016 20:21:38 GMT -5
|
|
|
Post by mnkdfann on Apr 8, 2016 23:37:46 GMT -5
I'm waiting to see a new job advert having to do with an opening in HR.
|
|
|
Post by lakers on Apr 9, 2016 1:58:24 GMT -5
Pfizer dropped Exubera on Oct 18, 2017, settled with Nektar on Nov 12, 2017, nearly a month later. www.wsj.com/articles/SB119269071993163273www.contractpharma.com/contents/view_breaking-news/2007-11-13/pfizer-nektar-reach-exubera-settlementPfizer said on the call with analysts yesterday that Exubera struggled because patients were resistant to beginning insulin therapy early in their disease, and were reluctant to visit the doctor for the lung-function tests required by regulators. Still, Pfizer promoted the drug until the bitter end. In July, the company rolled out slick television commercials with the catch line "Now I get it," to get patients comfortable with the inhaler. Earlier this week, Exubera was introduced in Canada. In 1998, Pfizer teamed with German company Hoechst Marion Roussel AG to make the insulin, and pledged to build a Frankfurt plant that would employ 200 people. Pfizer declined to say how much it spent on the Frankfurt facility and another in Terre Haute, Ind., but told investors yesterday that it would write off $454 million in fixed assets and $661 million in inventory. The charges sent its third-quarter profit down 77% to $761 million, or 11 cents a share, on revenue of $11.99 billion. Paris-based Sanofi-Aventis ultimately bought the German company and assumed its relationship with Pfizer, and the two companies presented Exubera to the U.S. Food and Drug Administration in 2005. At a meeting with analysts the following year, Ms. Katen told investors that their average forecast for Exubera sales in 2010 -- $1.15 billion -- was too low; Pfizer put it closer to $2 billion. World-wide sales for all insulin in 2006 were $8.7 billion, according to Credit Suisse. Last year, Exubera finally cleared regulatory review but with a label that cautioned against its use by smokers or asthmatics and recommended regular lung exams. Pfizer bought out Sanofi's share of the product for $1.3 billion. The news that Pfizer was abandoning Exubera came as a surprise to Nektar of San Carlos, Calif., from which Pfizer licensed Exubera. Nektar issued a scathing news release late yesterday accusing its partner of a poor marketing job and of not alerting Nektar it would be terminating their licensing deal. Pfizer says it told Nektar of its plans minutes after releasing the news, because the announcement was material for both companies. MNKD ASH is May 19, 2016, 1.5 months from 4/5/2016 Afrezza independent day. Hopefully, a settlement will be reached before 5/19/2016. m.facebook.com/MannKind-Corporation-237759248628/Pfizer spent more than $2.5B, TV Ads, expansion in Canada, and still paid Nektar $135M settlement. Pfizer makes nice with Nektar It’s not surprising that Pfizer has settled with nice package of $135 million for withdrawing from the Exubera contract. (See details of settlement at www.biospace.com/news_story.aspx?NewsEntityId=77240 ) Pfizer is rightfully concerned about losing its status as a “preferred partner” for potential future lucrative licensing deals with biopharma companies. This status allowed them to gain licenses for blockbusters Lipitor and Celebrex from Parke Davis and Searle, respectively, companies which Pfizer eventually acquired. audreysnetwork.wordpress.com/tag/pfizer-settlement-with-nektar/
|
|
|
Post by peppy on Apr 9, 2016 8:25:57 GMT -5
aged hippee, I too in a sense am also an aged hippee. How the hell did you do that? <--- still alive and learning. Pep
|
|
|
Post by kball on Apr 9, 2016 8:36:13 GMT -5
I'm more inclined to believe settlement due shortly. But less inclined to believe what amounts to an attempt to franchise Afrezza globally will work on a grand scale.
Can anyone remember a drug successfully marketed this way (let alone achieving blockbuster status) after an initial one country rollout went so poorly?
Matt? Bioexec25? Any Dr's on board wanna chime in?
|
|
|
Post by agedhippie on Apr 9, 2016 9:15:14 GMT -5
aged hippee, I too in a sense am also an aged hippee. How the hell did you do that? <--- still alive and learning. Pep
The trick is to pick an unlikely phrase, I used a chunk of the osteoporosis bullet point, and feed it to Google. It's often interesting to see how things and people are cross-linked. Open-source intelligence is a wonderful thing and why I'm not on social media.
|
|
|
Post by agedhippie on Apr 9, 2016 9:39:19 GMT -5
Pfizer dropped Exubera on Oct 18, 2017, settled with Nektar on Nov 12, 2017, nearly a month later. Pfizer spent more than $2.5B, TV Ads, expansion in Canada, and still paid Nektar $135M settlement. Pfizer makes nice with Nektar It’s not surprising that Pfizer has settled with nice package of $135 million for withdrawing from the Exubera contract. (See details of settlement at www.biospace.com/news_story.aspx?NewsEntityId=77240 ) Pfizer is rightfully concerned about losing its status as a “preferred partner” for potential future lucrative licensing deals with biopharma companies. This status allowed them to gain licenses for blockbusters Lipitor and Celebrex from Parke Davis and Searle, respectively, companies which Pfizer eventually acquired. audreysnetwork.wordpress.com/tag/pfizer-settlement-with-nektar/Pfizer had little option but to settle as they broke their contract whereas Sanofi exercised the break clause in their contract - one is a clear breach of contract the other equally clearly isn't. Pfizer would have been killed in court and that's why Pfizer settled. Sanofi did a better job with their contract and avoided these problems.
|
|